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If the negative association between pre-eclampsia and subsequent breast cancer risk differs by gender, this would strengthen the
hypothesis that factors intrinsic to the particular pregnancy may explain the association. The study included 701006 parous
Norwegian women with follow-up for breast cancer through the Cancer Registry of Norway. Breast cancer risk was lower in women
with pre-eclampsia/hypertension in their first pregnancy, compared to other women (relative risk, 0.86, 95% CI, 0.78–0.94), after
adjustment for age at first birth, maternal birth year, length of gestation, marital status, and parity. The risk reduction was slightly
greater if the woman delivered a son as opposed to a daughter (relative risks of 0.79 vs 0.94, P-value for interaction, 0.06), and if pre-
eclampsia/hypertension was combined with pre-term delivery, these differences were more pronounced (relative risks, 0.62 vs 1.07,
P-value for interaction 0.03). A subanalysis among 176036 primiparous women showed a substantial risk reduction if the mother
delivered a son (relative risk, 0.62, 95% CI, 0.47–0.82), but essentially null if she delivered a daughter (relative risk, 0.92, 95% CI,
0.72–1.18; P-value for interaction, 0.05). These results suggest that the effect of pre-eclampsia/hypertension may be attributed to
factors associated with the particular pregnancy rather than an underlying biological trait of the mother. The stronger risk reduction
related to having a son suggests a role for sex-dependent hormones in pregnancy.
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Women who are diagnosed with pre-eclampsia in pregnancy may
have a lower risk for breast cancer later in life compared to other
parous women (Polednak and Janerich, 1983; Thompson et al,
1989; Troisi et al, 1998; Cohn et al, 2001; Vatten et al, 2002a,b)
although a higher risk has also been reported (Paltiel et al, 2004).
Women who develop pre-eclampsia tend to have higher levels
of androgens and lower oestrogen and progesterone levels than
women in normotensive pregnancies (Innes and Byers, 1999).
These findings have been linked to a deficiency in aromatisation of
androgens in the placenta, which are suggested to be of importance
for the reduced risk of breast cancer associated with pre-eclampsia
(Troisi et al, 1998; Hoover and Troisi, 2001).
The influence of pre-eclampsia on subsequent breast cancer risk
could be attributed to factors associated with the particular
pregnancy, but the effect could also reflect an underlying biological
trait in a woman that decreases the risk for developing breast
cancer. One approach that may distinguish between these
possibilities would be to study whether the association with pre-
eclampsia is modified by pregnancy-specific factors, for example
offspring gender. If breast cancer risk associated with pre-
eclampsia differs according to gender of the offspring the
hypothesis that the effect of pre-eclampsia could originate from
that particular pregnancy would be strengthened.
In a cohort of 701006 women in Norway, pregnancy-related
information from the Medical Birth Registry was linked to the
National Cancer Registry. The aim of the study was to compare
breast cancer risk in women who had experienced pre-eclampsia
or hypertension in their first pregnancy to the risk of women who
were normotensive, and to study whether gender of the offspring
modifies the association.
MATERIALS AND METHODS
Data were derived from the Medical Birth Registry of Norway
that comprises all births since 1967, and the Norwegian Cancer
Registry, which has registered incident cancers since 1953.
Midwives and doctors complete a standardised form to notify
the Medical Birth Registry about each birth in the country
(www.mbr.no). Pre-eclampsia and gestational hypertension were
recorded as indicated in the standardised form of the Medical Birth
Registry and described elsewhere (Lie et al, 1998). The reporting of
cancer to the Cancer Registry by doctors or hospital departments
is mandatory and regulated by law (www.kreftregisteret.no). Using
the unique identification number of Norwegian citizens, we linked
all women registered at the Medical Birth Registry to the national
Cancer Registry, and identified women who had developed cancer
after delivery. A total of 751581 women were recorded with a
singleton first birth in the Medical Birth Registry between 1967 and
1998. Women with missing or improbable combinations of the
offspring’s sex, gestational age or birth weight in their first delivery
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women who delivered before 22 weeks of gestation or whose
offspring’s birth weight was less than 500g (n¼880). Women
diagnosed with cancer before the beginning of follow-up
(n¼1345), and women lost to follow-up (n¼320) were also
excluded, leaving 701006 women for analysis. For these women
information was available on length of gestation, birth weight,
and the offspring’s gender. By linkage to the Cancer Registry, we
followed these women from the time of delivery (1967–1998) until
the diagnosis of cancer, until death from any cause, or to the end of
follow-up (31 December, 2002), whichever occurred first.
Most cases of pre-eclampsia occur in the first pregnancy, and
including subsequent pregnancies in the analysis might introduce
methodological problems that may interfere with the aim of the
study. In a subgroup analysis, we therefore analysed the data
separately for the 176036 women who remained primiparous
throughout the study period.
We calculated hazard ratios as estimates of the relative risk for
breast cancer among women who had experienced pre-eclampsia
or hypertension in the index pregnancy compared to the risk of
normotensive women. Further, we stratified the analysis by the
offspring’s gender, to study whether the association between pre-
eclampsia and breast cancer risk differed between women who
delivered a son or a daughter. In some analyses, we also stratified
pre-eclampsia according to pre-term (o37 weeks of gestation) or
term (X37 weeks) delivery. In the analysis, we adjusted for potential
confounding by the women’s year of birth (5 year categories), age at
delivery (5 year categories), length of gestation (completed weeks),
parity, and marital status, using Cox regression analysis (Stata
Statistical Software: Release 9, College Station, TX, USA). Precision
of the relative risks was estimated by 95% confidence intervals, and
the interaction between pre-eclampsia and offspring gender was
statistically tested in the regression model.
RESULTS
During follow-up, a total of 9160 incident cases of breast cancer
were diagnosed among 701006 women (Table 1). Among cases,
503 were diagnosed among 43286 women with pre-eclampsia or
hypertension in pregnancy. Compared to normotensive women,
the risk of breast cancer was lower among women who had pre-
eclampsia or gestational hypertension in their first pregnancy
(relative risk 0.86, 95% CI, 0.78–0.94), after adjustment for
maternal birth year, age at delivery, length of gestation, parity, and
marital status.
In women who delivered a son, the risk reduction was slightly
greater (relative risk 0.79, 95% CI, 0.69–0.90) than for women who
had a daughter (relative risk 0.94, 95% CI, 0.82–1.06), but the test
for interaction was of borderline significance (P¼0.06). If pre-
eclampsia/hypertension was combined with pre-term delivery, the
risk reduction associated with having a son and not a daughter was
even greater (relative risks, 0.62 vs 1.07, P-value for interaction
0.03).
In a subgroup of 176036 women who remained primiparous
throughout the study period, a total of 1916 incident cases of
breast cancer were diagnosed during follow-up, and 121 of these
cases occurred among the 11945 women who had pre-eclampsia or
hypertension in pregnancy (Table 2). Similar to the finding for the
whole population the risk of breast cancer was lower among
women who had pre-eclampsia or gestational hypertension
(relative risk 0.75, 95% CI, 0.62–0.91), after adjustment for age,
age at delivery, length of gestation, and marital status. Also in
primiparous women, those who delivered a son had a stronger
reduction in breast cancer risk (relative risk 0.62, 95% CI, 0.47–
0.82) compared to women who delivered a daughter (relative risk
0.92, 95% CI, 0.72–1.18; P-value for interaction 0.05). Further
stratification by gestational age (pre-term or term pre-eclampsia)
among the primiparous women was not calculated because of
the small number of breast cancers in women with pre-term
pre-eclampsia.
DISCUSSION
We found that the reduced risk of breast cancer associated with
pre-eclampsia or hypertension in first pregnancy was substantial
among women who had a son, but essentially null in women who
delivered a daughter. Previous studies have also shown an inverse
association related to pre-eclampsia (Polednak and Janerich, 1983;
Thompson et al, 1989; Troisi et al, 1998; Cohn et al, 2001; Vatten
et al, 2002a,b), but no previous study has assessed whether the
offspring’s gender could modify this association.
Clinical information included in health registries is rarely
validated, partly because a gold standard for the diagnosis is not
available. Although this may be a weakness of this study, it is
equally clear that the diagnosis of pre-eclampsia (or gestational
hypertension) in the Medical Birth Registry did not depend on
future diagnosis of breast cancer. Consequently, any bias in the
association between pre-eclampsia or gestational hypertension and
subsequent breast cancer risk is likely to be non-differential, and
lead to underestimates of the real effect.
Table 1 Relative risk of breast cancer, comparing women who had pre-eclampsia or gestational hypertension in their first pregnancy, and women who
were normotensive, by gender of the offspring
Characteristics of pregnancy No. of women Breast cancer Relative risk (95% CI)
All pregnancies
Normotensive 657720 8657 1.0 (Reference)
Pre-eclampsia or hypertension 43286 503 0.86
a (0.78–0.94)
Pre-term
c pre-eclampsia/ hypertension 5482 60 0.84
a (0.64–1.09)
Male offspring
Normotensive 338129 4468 1.0 (Reference)
Pre-eclampsia or hypertension 22984 246 0.79
b (0.60–0.90)
Pre-term
c pre-eclampsia/Hypertension 2956 24 0.62
b (0.42–0.95)
Female offspring
Normotensive 319591 4194 1.0 (Reference)
Pre-eclampsia or hypertension 20302 252 0.94
b (0.82–1.06)
Pre-term
c preeclampsia/hypertension 2526 36 1.07
b (0.75–1.52)
aAdjusted for maternal age, age at first birth, length of gestation, parity, marital status, and offspring gender.
bAdjusted for maternal age, age at first birth, length of gestation, parity,
and marital status.
cPre-term: delivery before 37 weeks of gestation. CI ¼ confidence interval. Significance test for interaction between pre-eclampsia and offspring gender,
P¼0.06. Significance test for interaction between pre-term pre-eclampsia/hypertension and offspring gender, P¼0.03.
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reduce the pregnancy-related protection against breast cancer
(Vatten et al, 2002a,b), indicating that mechanisms operating
during the third trimester (e.g. the androgen surge at term) are
particularly important for protection. Pre-eclampsia in its severe
form often results in early induction of delivery so it is appropriate
to account for length of gestation. In our study, however, adjustment
for gestational length did not appreciably change the results.
An inverse association between pre-eclampsia and breast cancer
risk has now been confirmed in a number of studies. It is, however,
not clear if the reduction in risk is attributable to long-term effects
of the particular pregnancy, or whether women who develop pre-
eclampsia exhibit an underlying biological trait that is somehow
protective against breast cancer development.
A combination of genetic susceptibility and abnormal placenta-
tion is thought to constitute the basis for pre-eclampsia, but
clinically, the severity of the syndrome depends on degree of
hypertension and proteinuria from 20 weeks of gestation and
onwards. Pre-eclampsia is characterised by a disturbance in the
fundamental balance between steroid and other pregnancy
hormones during pregnancy (Roberts and Cooper, 2001). Maternal
androgen levels appear to be higher than in normotensive
pregnancies, and levels of oestrogen and progesterone appear to
be lower. Thus, it has been suggested that the reduced risk of
breast cancer associated with pre-eclampsia could be attributed to
lower concentrations of oestrogen and progesterone (Innes and
Byers, 1999). It has also been suggested that an androgen influence
associated with the pre-eclamptic condition may be important
(Hoover and Troisi, 2001). Future research needs to address the
cyclical fluctuation of hormones in women who have had a
diagnosis of pre-eclampsia compared to normotensive women.
This research would best be conducted in primiparous women to
reduce hormonal influences of subsequent pregnancies.
Our results suggest that the protective effect associated with
pre-eclampsia was restricted to women who delivered a son. This
finding may support the hypothesis that a protective effect of pre-
eclampsia on breast cancer risk could originate from the particular
pregnancy, rather than indicating an underlying biological trait
that is protective against breast cancer in women who develop
pre-eclampsia.
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